GlaxoSmithKline sees light at end of Advair tunnel

LONDON (Reuters) - GlaxoSmithKline sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news